Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
The CPT® Code 88275 refers to a laboratory test that focuses on molecular cytogenetics through the technique of interphase in situ hybridization. This procedure is designed to analyze a sample of 100 to 300 cells, which can be derived from various biological sources such as bone marrow, blood, amniotic fluid, chorionic villi, and other body tissues or tumors. Molecular cytogenetics is a branch of genetics that studies the structure and function of chromosomes, including their abnormalities and variations within the genome. The interphase in situ hybridization method, specifically interphase fluorescence in situ hybridization (I-FISH), allows for the examination of the nuclei of eukaryotic cells, providing insights into a wider range of cell types. Samples for this test are typically obtained through procedures that are reported separately, including venipuncture, bone marrow aspiration, amniocentesis, chorionic villus sampling, and biopsy. The analysis performed using this code is crucial for rapid detection of chromosomal aneuploidies, particularly for chromosomes X, Y, 13, 18, and 21, in maternal amniotic fluid or chorionic villi, as well as in whole blood from infants. Additionally, this test plays a significant role in the risk stratification of patients with newly diagnosed or relapsed multiple myeloma, the detection of genomic abnormalities in chronic lymphocytic leukemia, and the diagnosis and classification of hematopoietic neoplasms presenting with eosinophilia. Furthermore, the examination of blood and bone marrow samples can support the diagnosis of acute lymphocytic leukemia and confirm the presence of PML-RARA translocation in acute promyelocytic leukemia. It is also utilized to exclude cryptic BCR-ABL1 rearrangements in myelogenous leukemia patients or PDGFRA abnormalities in those with neoplastic eosinophilia. The test is instrumental in diagnosing and predicting aggressive morphologic features in cases of Burkitt lymphoma versus diffuse large B-cell lymphoma, as well as monitoring minimal residual disease in therapy-related myelodysplastic syndrome (MDS) or acute myelogenous leukemia associated with MDS. Lastly, whole blood samples may be analyzed to identify significant translocations in patients newly diagnosed with acute myeloid leukemia. It is important to note that CPT® Code 88274 is applicable when analyzing 25-99 cells, while CPT® Code 88275 is specifically designated for the analysis of 100-300 cells.
© Copyright 2026 Coding Ahead. All rights reserved.
The procedure associated with CPT® Code 88275 is indicated for various clinical scenarios where molecular cytogenetic analysis is necessary. The following conditions and situations warrant the use of this test:
The procedure for CPT® Code 88275 involves several critical steps to ensure accurate molecular cytogenetic analysis. The following outlines the procedural steps:
After the procedure associated with CPT® Code 88275, the following post-procedure considerations are important:
Patients may require monitoring for any potential complications related to the sample collection method used, such as bleeding or infection, particularly in cases of bone marrow aspiration or biopsy. The results of the molecular cytogenetic analysis will typically be communicated to the referring physician, who will discuss the findings with the patient and determine the next steps in management based on the results. It is essential for healthcare providers to integrate the findings from this test with other clinical data to guide treatment decisions, risk assessment, and further diagnostic evaluations as necessary. Follow-up appointments may be scheduled to review results and discuss implications for treatment or additional testing.
| Short Descr | CYTOGENETICS 100-300 | Medium Descr | MOLEC CYTG INTERPHASE ISH ANALYZE 100-300 CLL | Long Descr | Molecular cytogenetics; interphase in situ hybridization, analyze 100-300 cells | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Conditionally packaged laboratory tests | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | T1H - Lab tests - other (non-Medicare fee schedule) | MUE | 12 | CCS Clinical Classification | 235 - Other Laboratory |
| 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. | 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. | GZ | Item or service expected to be denied as not reasonable and necessary | 91 | Repeat clinical diagnostic laboratory test: in the course of treatment of the patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results. under these circumstances, the laboratory test performed can be identified by its usual procedure number and the addition of modifier 91. note: this modifier may not be used when tests are rerun to confirm initial results; due to testing problems with specimens or equipment; or for any other reason when a normal, one-time, reportable result is all that is required. this modifier may not be used when other code(s) describe a series of test results (eg, glucose tolerance tests, evocative/suppression testing). this modifier may only be used for laboratory test(s) performed more than once on the same day on the same patient. | GA | Waiver of liability statement issued as required by payer policy, individual case | Q1 | Routine clinical service provided in a clinical research study that is in an approved clinical research study | XU | Unusual non-overlapping service, the use of a service that is distinct because it does not overlap usual components of the main service | XE | Separate encounter, a service that is distinct because it occurred during a separate encounter | TC | Technical component; under certain circumstances, a charge may be made for the technical component alone; under those circumstances the technical component charge is identified by adding modifier 'tc' to the usual procedure number; technical component charges are institutional charges and not billed separately by physicians; however, portable x-ray suppliers only bill for technical component and should utilize modifier tc; the charge data from portable x-ray suppliers will then be used to build customary and prevailing profiles | 26 | Professional component: certain procedures are a combination of a physician or other qualified health care professional component and a technical component. when the physician or other qualified health care professional component is reported separately, the service may be identified by adding modifier 26 to the usual procedure number. | 76 | Repeat procedure or service by same physician or other qualified health care professional: it may be necessary to indicate that a procedure or service was repeated by the same physician or other qualified health care professional subsequent to the original procedure or service. this circumstance may be reported by adding modifier 76 to the repeated procedure or service. note: this modifier should not be appended to an e/m service. | AQ | Physician providing a service in an unlisted health professional shortage area (hpsa) | GC | This service has been performed in part by a resident under the direction of a teaching physician | GW | Service not related to the hospice patient's terminal condition | GY | Item or service statutorily excluded, does not meet the definition of any medicare benefit or, for non-medicare insurers, is not a contract benefit | Q0 | Investigational clinical service provided in a clinical research study that is in an approved clinical research study | XS | Separate structure, a service that is distinct because it was performed on a separate organ/structure |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2011-01-01 | Changed | Short description changed. |
| 1999-01-01 | Added | First appearance in code book in 1999. |
Get instant expert-level medical coding assistance.